Global Gastric Cancer Drugs Market Opportunities And Strategies For Major Players In The Gastric Cancer Drugs Market 2021-2030
20 Aug, 2021
The gastric cancer drugs market consists of sales of gastric cancer drugs and related services by entities (organizations, sole traders and partnerships) that produce gastric cancer drugs to prevent, diagnose and treat gastric cancer. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating gastric cancer.
Global Gastric Cancer Drugs Market Size And Drivers:
The global gastric cancer drugs market reached a value of nearly $2,516.2 million in 2020, having decreased at a compound annual growth rate (CAGR) of -13.6% since 2015. The market is expected to grow from $2,516.2 million in 2020 to $3,914.8 million in 2025 at a rate of 9.2%. The market is then expected to grow at a CAGR of 4.3% from 2025 and reach $4,832.0 million in 2030. The rise in the number of gastric cancer cases across the globe is likely to contribute to the growth of the gastric cancer drugs market during the forecast period.
Request For A Sample For The Global Gastric Cancer Drugs Market Report:
Trends In The Global Gastric Cancer Drugs Market
Many companies in the gastric cancer drugs market are strategically partnering and collaborating with other companies to broaden their product portfolios and expand their gastric cancer drugs business. These collaborations are helping drug manufacturing companies to enhance their product strength in specific therapy areas. For instance, Basilea Pharmaceutica entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company for the use of the anti-VEGFR2 antibody ramucirumab (CYRAMZA®) 1 in the ongoing multi-cohort phase 1/2 study FIDES-03 with the FGFR inhibitor derazantinib in advanced gastric (stomach) cancer patients with FGFR genetic aberrations.
Global Gastric Cancer Drugs Market Segments:
The global gastric cancer drugs market is further segmented based on type, end user, route of administration and geography.
By Type: Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab
By End User: Hospitals, Clinics, Others
By Route of Administration: Oral, Parenteral
By Geography: The global gastric cancer drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America is the largest region in the global gastric cancer drugs market, accounting for 35.0% of the total in 2020.
Read More On The Report For The Global Gastric Cancer Drugs Market At:https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market
Gastric Cancer Drugs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides gastric cancer drugs market overviews, analyzes and forecasts market size and growth for the global gastric cancer drugs market, gastric cancer drugs market share, gastric cancer drugs market players, gastric cancer drugs market segments and geographies, gastric cancer drugs market’s leading competitors’ revenues, profiles and market shares. The gastric cancer drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.